Barclays analyst Luke Sergott lowered the firm’s price target on Agilent to $105 from $110 and keeps an Underweight rating on the shares. The analyst previewed the Q3 earnings reports for the life science tools and diagnostics sector and dug into bioprocessing destocking and the risk of National Institutes of Health budget cuts.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on A:
- Agilent initiated with a Market Perform at Bernstein
- Illumina appoints Jacob Thaysen as new CEO
- Abcam’s (NASDAQ: ABCM) Stock Dips after Danaher Corp’s $5.7 Billion Acquisition Bid
- Danaher in lead in bidding to acquire Abcam, Reuters reports
- Agilent receives European IVDR certification for companion diagnostic assay